Decreasing Efficacy of Antimalarial Combination Therapy in Uganda Is Explained by Decreasing Host Immunity Rather than Increasing Drug Resistance

Chloroquine-resistance molecular markers (Pfcrt T76 and Pfmdr-1 Y86) and amodiaquine resistance in Burkina Faso

(2010) Halidou Tinto et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Long-Term Asymptomatic Carriage of Plasmodium falciparum Protects from Malaria Attacks: a Prospective Study among Senegalese Children

(2008) S. Males et al.   CLINICAL INFECTIOUS DISEASES

Factors Determining the Heterogeneity of Malaria Incidence in Children in Kampala, Uganda

(2008) Tamara D. Clark et al.   JOURNAL OF INFECTIOUS DISEASES

Emergence of adhfrMutation Conferring High‐Level Drug Resistance inPlasmodium falciparumPopulations from Southwest Uganda

(2008) Caroline Lynch et al.   JOURNAL OF INFECTIOUS DISEASES

A new global malaria eradication strategy

(2008) Richard Feachem et al.   LANCET

The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea

(2008) Jutta Marfurt et al.   MALARIA JOURNAL

Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials

(2008) Lucy C Okell et al.   MALARIA JOURNAL

Clinically immune hosts as a refuge for drug-sensitive malaria parasites

(2008) Eili Y Klein et al.   MALARIA JOURNAL

Immunity to malaria: more questions than answers

(2008) Jean Langhorne et al.   NATURE IMMUNOLOGY

The Limits and Intensity of Plasmodium falciparum Transmission: Implications for Malaria Control and Elimination Worldwide

(2008) Carlos A Guerra et al.   PLOS MEDICINE